The vast majority of pharmaceutical and biotechnology companies operating in the US today are ill-prepared to justify the product value claims they make to managed care organizations with sound pharmacoeconomic data, according to a new report, Managed Markets 2007: Pharmaceutical Reimbursement Strategy, Organizational Structure and Medicare Part D, from pharmaceutical business intelligence group Cutting Edge Information.
The report says that "most mid-size and small pharmas and biotechs lack the managed markets marketing resources to drive their clinical development organizations to incorporate pharmacoeconomic (PE) end points into Phase III clinical trials. Many managed markets departments - even those at some multi-billion-dollar global drug companies - have as many as 50 to 75 managed market account managers and support staff, yet they have only one or two marketers."
Other key findings from the report, which is available on-line at: www.pharmamanagedmarkets.com, include:
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze